Sign in to fuzzto save your conversations, follow your research and come back anytime.
Nath Bio-Genes
NATHBIOGEN
NSE
BSE
NSEBSESectorFMCG
153.06
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Revenue and gross profit rise in Q1 FY27, but EBITDA and PAT decline amid margin compression.
Revenue grew from ₹2,802 Cr in Q1 FY26 to ₹3,228 Cr in Q1 FY27, reflecting strong seasonal demand
EBITDA margin compressed from 14% in Q1 FY26 to 11% in Q1 FY27, reflecting margin pressure
Gross profit expanded from ₹1,438 Cr in Q1 FY26 to ₹1,629 Cr in Q1 FY27, confirming volume recovery
Gross margin slipped from 51% in Q1 FY26 to 50% in Q1 FY27, indicating pricing pressure
Paddy revenue share rose from 30% in Q1 FY26 to 35% in Q1 FY27, highlighting growing crop demand
EPS rebounded from ₹3.8 in Q3 FY26 to ₹17.18 in Q1 FY27, showing resilient earnings power
Finance cost eased from ₹42 Cr in Q3 FY26 to ₹38 Cr in Q1 FY27, suggesting improved debt management